Skip to main content
. Author manuscript; available in PMC: 2012 Nov 15.
Published in final edited form as: Cancer Res. 2011 Oct 11;71(22):7080–7090. doi: 10.1158/0008-5472.CAN-11-2009

Figure 3. JO-1 improves penetration of trastuzumab in HCC1954 breast cancer tumors in situ.

Figure 3

Tumor bearing mice were intravenously injected with PBS or JO-1 (2 mg/kg) followed by trastuzumab 1 h later. Tumors were harvested 1 h or 12 h after trastuzumab injection. A) Sections were stained for human IgG (i.e. trastuzumab). Positive staining appears green. The scale bar is 20 μm. B) Western blot analysis for human IgG (trastuzumab) in tumors. Heavy (HC) and light (LC) Ig chains are indicated by arrows. C) ELISA for human IgG1 in tumor lysates. Total protein concentration in all lysates was adjusted to 5 mg/ml. Shown is the ratio of human IgG1 concentrations in tumors of PBS treated mice vs mice that received JO-1 and/or trastuzumab treatment. n=3, * p<0.05